# Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

> **NCT04338438** · PHASE2 · COMPLETED · sponsor: **Beijing Friendship Hospital** · enrollment: 37 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Apatinib Mesylate tablets combined with S-1 capsules

## Key facts

- **NCT ID:** NCT04338438
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-01
- **Primary completion:** 2019-04-30
- **Final completion:** 2020-01-31
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2020-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04338438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04338438, "Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04338438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*